Companies › Tiohundra
2 active drug programs in 40 registered trials: 20 Phase 4, 12 Phase 3, 6 Phase 2, 2 Phase 1; Cardiovascular, Genitourinary, Infectious disease, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Hydrocortisone Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Pituitary Adenoma; Adrenal Insufficiency; Shock … | Jan 2027 |
| Vasopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock … | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06934798 | Vasopressin | Phase 4 | Vasoplegic Syndrome of Cardiac Surgery | Cardiovascular | Jul 2025 |
| NCT06547892 | Vasopressin | Phase 2 | Critical Illness | Other | Oct 2025 |
| NCT04591990 | Hydrocortisone | Phase 3 | Postresuscitation Syndrome | Metabolic and endocrine | Dec 2025 |
| NCT05668455 | Hydrocortisone | Phase 3 | Ocular Inflammation | Immunology | Dec 2025 |
| NCT06679816 | Hydrocortisone | Phase 4 | Pituitary Adenoma | Oncology | Dec 2025 |
| NCT05193396 | Hydrocortisone | Phase 4 | Adrenal Insufficiency | Genitourinary | Jan 2026 |
| NCT05816226 | Hydrocortisone | Phase 3 | TMJ Pain | Other | Jan 2026 |
| NCT04404400 | Hydrocortisone | Phase 3 | Critical Illness Related Corticosteroids Insufficiency | Metabolic and endocrine | Feb 2026 |
| NCT05568160 | Vasopressin | Phase 3 | Scheduled Cardiac Surgery With Extracorporeal Circulation | Cardiovascular | Mar 2026 |
| NCT07248761 | Hydrocortisone | Phase 4 | Shock | Infectious disease | Jun 2026 |
| NCT06982183 | Hydrocortisone | Phase 4 | Fear of Spiders | Psychiatry | Sep 2026 |
| NCT07102615 | Vasopressin | Phase 4 | Retained Products of Conception | Other | Dec 2026 |
| NCT02118467 | Vasopressin | Phase 4 | Shock | Cardiovascular | Dec 2026 |
| NCT07124650 | Hydrocortisone | Phase 4 | Postoperative Sore Throat, Cough, Hoarseness | Metabolic and endocrine | Dec 2026 |
| NCT03446456 | Vasopressin | Phase 1 | Acute Pain | Metabolic and endocrine | Dec 2026 |
| NCT03760835 | Hydrocortisone | Phase 4 | Congenital Adrenal Hyperplasia | Genitourinary | Dec 2026 |
| NCT03401398 | Hydrocortisone | Phase 3 | Septic Shock | Infectious disease | Dec 2026 |
| NCT05160506 | Hydrocortisone | Phase 2 | Pancreatitis | Gastroenterology | Jan 2027 |
| NCT05139849 | Vasopressin | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial | Cardiovascular | Jan 2027 |
| NCT05139849 | Hydrocortisone | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial | Cardiovascular | Jan 2027 |
| NCT05958342 | Vasopressin | Phase 2 | Trauma | Metabolic and endocrine | Mar 2027 |
| NCT06895473 | Hydrocortisone | Phase 2 | Hematopoietic and Lymphatic System Neoplasm | Oncology | Apr 2027 |
| NCT06709573 | Vasopressin | Phase 4 | Sepsis | Infectious disease | May 2027 |
| NCT06709573 | Vasopressin | Phase 4 | Sepsis | Infectious disease | May 2027 |
| NCT06344442 | Vasopressin | Phase 3 | Acute Kidney Injury Post Liver Transplantation | Genitourinary | May 2027 |
| NCT00859781 | Hydrocortisone | Phase 2 | Prostate Cancer | Oncology | Jun 2027 |
| NCT04082533 | Hydrocortisone | Phase 4 | Pain | Immunology | Jul 2027 |
| NCT06464510 | Vasopressin | Phase 3 | Septic Shock | Metabolic and endocrine | Aug 2027 |
| NCT07262957 | Hydrocortisone | Phase 4 | Pancreas Head Cancer | Oncology | Sep 2027 |
| NCT05836610 | Hydrocortisone | Phase 4 | Hypoxic-Ischemic Encephalopathy | Cardiovascular | Sep 2027 |
| NCT07052084 | Vasopressin | Phase 3 | Septic Shock | Other | Feb 2028 |
| NCT05738148 | Vasopressin | Phase 1 | Cardiac Arrest Neonatal | Cardiovascular | Feb 2028 |
| NCT05435781 | Hydrocortisone | Phase 4 | Adrenal Insufficiency | Genitourinary | Mar 2028 |
| NCT07763210 | Hydrocortisone | Phase 2 | Non-hodgkin Lymphoma | Oncology | Mar 2028 |
| NCT07037043 | Hydrocortisone | Phase 3 | Inflammation in Cardiac Surgery | Cardiovascular | May 2028 |
| NCT07383103 | Hydrocortisone | Phase 4 | Septic Shock | Other | Dec 2028 |
| NCT06881927 | Hydrocortisone | Phase 4 | Sepsis and Septic Shock | Infectious disease | Aug 2029 |
| NCT02775227 | Hydrocortisone | Phase 4 | Pancreatic Fistula | Oncology | Dec 2029 |
| NCT06892197 | Hydrocortisone | Phase 4 | Community Acquired Pneumonia (CAP) | Respiratory | Aug 2030 |
| NCT06892210 | Hydrocortisone | Phase 4 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Aug 2030 |
Insud Pharma Brainfarma Industria Química e Farmacêutica S/A Optinose US Laboratorio Elea Phoenix Biocodex
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.